{"id":3202,"date":"2013-11-07T07:30:00","date_gmt":"2013-11-07T07:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/delarsrapport-januari-september-2013\/"},"modified":"2013-11-07T07:30:00","modified_gmt":"2013-11-07T07:30:00","slug":"delarsrapport-januari-september-2013","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/","title":{"rendered":"Del\u00e5rsrapport januari\u2013september 2013"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>Fortsatt stark f\u00f6rs\u00e4ljningstillv\u00e4xt och framsteg i registreringsprocessen av STEEN Solution\u2122 i USA.<\/strong><\/div>\n<\/p>\n<p><span><strong>V\u00c4SENTLIGA H\u00c4NDELSER UNDER TREDJE KVARTALET<\/strong><\/span><\/p>\n<ul>\n<li><span>Bolaget hade ett m\u00f6te med FDA d\u00e4r det meddelats att ett expertpanelm\u00f6te kommer h\u00e5llas i b\u00f6rjan av 2014. Detta \u00e4r positivt d\u00e5 ett expertpanelm\u00f6te normalt f\u00f6reg\u00e5r ett registreringsbeslut och avslutar diskussion kring dokumentation.<\/span><\/li>\n<li><span>FDA beslutade att de i studien ing\u00e5ende klinikerna f\u00e5r forts\u00e4tta att transplantera lungor som perfunderats med STEEN Solution\u2122. Vid slutet av kvartalet hade sammanlagt 52 patienter i USA blivit transplanterade med lungor som gjorts tillg\u00e4ngliga genom anv\u00e4ndning av Steen Solution\u2122 och XVIVOs perfusionsmaskin XPS\u2122.<\/span><\/li>\n<li><span>Dr Joel Cooper tilltr\u00e4der som Medical Advisor f\u00f6r XVIVO Perfusion. Dr Joel Cooper var den f\u00f6rsta kirurgen i v\u00e4rlden som genomf\u00f6rde en lyckad lungtransplantation och \u00e4r internationellt erk\u00e4nd f\u00f6r sina banbrytande framsteg inom behandling av lungsjukdomar. Dr Cooper kommer tillf\u00f6ra sitt kliniska kunnande inom lungtransplantation och vara ett st\u00f6d f\u00f6r bolagets kliniska utveckling.<\/span><\/li>\n<li><span>Avtal f\u00f6r att flytta kontraktsproduktionen av STEEN Solution\u2122 har knutits under kvartalet. Detta kommer initialt medf\u00f6ra eng\u00e5ngskostnader p\u00e5 cirka 1 MSEK, men kommer inom ett \u00e5r medf\u00f6ra f\u00f6rb\u00e4ttrade bruttomarginaler p\u00e5 produkten. <\/span><\/li>\n<\/ul>\n<p><span><strong>TREDJE KVARTALET (JUL-SEP 2013)<\/strong><\/span><\/p>\n<ul>\n<li><span>Oms\u00e4ttnings\u00f6kningen var 19 procent i lokala valutor. F\u00f6rs\u00e4ljningen var det h\u00f6gsta n\u00e5gonsin f\u00f6r ett enskilt kvartal och uppgick till 16,8 MSEK (14,4*), motsvarande en \u00f6kning om 17 procent i SEK. <\/span><\/li>\n<li><span>R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 3,8 MSEK (-1,5*) motsvarande en EBITDA marginal om 23 procent.<\/span><\/li>\n<li><span>Nettoresultatet uppgick till 1,6 MSEK, vilket gav ett resultat per aktie om 0,08 SEK. <\/span><\/li>\n<li><span>Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var -1,5 MSEK p\u00e5 grund av 5.3 MSEK lageruppbyggnad. <\/span><\/li>\n<\/ul>\n<p><span><strong>PERIODEN (JAN-SEP 2013)<\/strong><\/span><\/p>\n<ul>\n<li><span>Oms\u00e4ttnings\u00f6kningen var 20 procent i lokala valutor. F\u00f6rs\u00e4ljningen uppgick till 48,9 MSEK (42,2*), motsvarande en \u00f6kning om 16 procent i SEK. <\/span><\/li>\n<li><span>R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 10,0 MSEK (7,7*) motsvarande en EBITDA marginal om 20 procent.<\/span><\/li>\n<li><span>Nettoresultatet uppgick till 5,7 MSEK, vilket gav ett resultat per aktie om 0,29 SEK. <\/span><\/li>\n<li><span>Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var 6,4 MSEK. <\/span><\/li>\n<\/ul>\n<p><span><strong>V\u00c4SENTLIGA H\u00c4NDELSER EFTER KVARTALETS UTG\u00c5NG<\/strong><\/span><\/p>\n<ul>\n<li><span>Den f\u00f6rsta transplantationen i Asien med hj\u00e4lp av STEEN Solution\u2122 genomf\u00f6rdes i oktober 2013.<\/span><\/li>\n<li><span>XVIVO Perfusion har beslutat att lansera XPS\u2122 systemet i Europa f\u00f6r att underl\u00e4tta anv\u00e4ndningen av STEEN Solution\u2122 p\u00e5 basis av goda kliniska resultat och ett stort intresse fr\u00e5n kliniker i Europa.<\/span><\/li>\n<li><span>En st\u00e4mning mot Vivoline inl\u00e4mnades den 11 oktober 2013 f\u00f6r att skydda XVIVO Perfusions r\u00e4ttigheter till patent avseende tre produkter uppfunna av Professor Stig Steen.<\/span><\/li>\n<\/ul>\n<p><span><strong>TELEFONKONFERENS<\/strong><\/span><\/p>\n<p><span><strong><strong>\u00a0<\/strong><\/strong>VD Magnus Nilsson presenterar rapporten vid en telefonkonferens klockan 14:00 torsdagen den 7 november 2013. Telefon: 08-50336434, ange kod 90670245<\/span><\/p>\n<p><span><span>* J\u00e4mf\u00f6relsetal 2012 \u00e4r Vitrolifes segment Transplantation s\u00e5 som det redovisats i Vitrolifes rapportering.<\/span><\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Magnus Nilsson, VD, tel: 031-788 21 50, e-post: <a href=\"mailto:magnus.nilsson@xvivoperfusion.com\" rel=\"nofollow\">magnus.nilsson@xvivoperfusion.com<\/a><\/span><br \/><span>Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: <a href=\"mailto:christoffer.rosenblad@xvivperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><br \/>F\u00f6r ytterligare information om Xvivo Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<p><span>Xvivo Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den 7\u00a0november 2013 kl. 08:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fortsatt stark f\u00f6rs\u00e4ljningstillv\u00e4xt och framsteg i registreringsprocessen av STEEN Solution\u2122 i USA. V\u00c4SENTLIGA H\u00c4NDELSER UNDER TREDJE KVARTALET Bolaget hade ett&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3202","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q3"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Del\u00e5rsrapport januari\u2013september 2013 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Del\u00e5rsrapport januari\u2013september 2013 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Fortsatt stark f\u00f6rs\u00e4ljningstillv\u00e4xt och framsteg i registreringsprocessen av STEEN Solution\u2122 i USA. V\u00c4SENTLIGA H\u00c4NDELSER UNDER TREDJE KVARTALET Bolaget hade ett...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-september-2013\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-september-2013\\\/\",\"name\":\"Del\u00e5rsrapport januari\u2013september 2013 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-11-07T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-september-2013\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-september-2013\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-september-2013\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Del\u00e5rsrapport januari\u2013september 2013\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Del\u00e5rsrapport januari\u2013september 2013 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/","og_locale":"en_US","og_type":"article","og_title":"Del\u00e5rsrapport januari\u2013september 2013 - XVIVO","og_description":"Fortsatt stark f\u00f6rs\u00e4ljningstillv\u00e4xt och framsteg i registreringsprocessen av STEEN Solution\u2122 i USA. V\u00c4SENTLIGA H\u00c4NDELSER UNDER TREDJE KVARTALET Bolaget hade ett...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/","name":"Del\u00e5rsrapport januari\u2013september 2013 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-11-07T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-september-2013\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Del\u00e5rsrapport januari\u2013september 2013"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}